HCQ Fails to Prevent COVID-19 in Randomized Trial |
Journal Updates
eMediNexus Coverage from: 
HCQ Fails to Prevent COVID-19 in Randomized Trial

4 Read Comments                

Hydroxychloroquine (HCQ) does not seem to reduce the risk for infection in people exposed to patients with confirmed COVID-19, revealed a randomized, double-blind, placebo-controlled prevention trial.

Investigators enrolled 821 asymptomatic participants from multiple sites in the United States and Canada. The incidence of new illness compatible with COVID-19 was not significantly different between those who received HCQ (49 of 414; 11.8%) and those who received placebo (58 of 407; 14.3); the absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2; P = .35). The findings were published in the New England Journal of Medicine.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now